CAG-hACE2-IRES-Luc-Tg

Nomenclature

C57BL/6Smoc-Tgtn(CAG-human ACE2-IRES-Luciferase-WPRE-polyA)Smoc

Cat. NO.

NM-TG-200002

Strain State

Repository Live

Export PDF

Model Description

The transgene is composed of a CAG-human ACE2-IRES-Luciferase-WPRE-polyA expression cassette under the control of CAG promter.
Research Application:corona virus related research

Validation Data

ACE2-HU.png

Figure 1. Luciferase expression of the CAG-hACE2-IRES-Luciferase transgenic mice.

ACE2-HU-wb-EN.jpg

Figure 2. Western blot analysis of  ACE2  protein from the CAG-hACE2-IRES-Luciferase transgenic mice. 

ace2-3.png

Figure 3. Virus titers in the lungs of hACE2 Tg mice after SARS-CoV-2 infection. Groups of hACE2 Tg mice and wild type mice were inoculated with the same dose of SARS-CoV-2, the result shows that hACE2 Tg mice were highly susceptible to SARS-CoV-2 infection.

image.png

Figure 4. Body weight change in hACE2 Tg mice after drug treatment.

image.png

Figure 5. The viral load in the lung tissues of hACE2 Tg mice after drug treatment. 


Publications 2piece


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more